Prognostic importance of thymidine kinase in colorectal and breast cancer

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1907-1909

  Svobodova, S ^a,b   Topolcan, O ^b,c   Holubec, L ^b   Treska, V ^b   Sutnar, A ^b   Rupert, K ^b   Kormunda, S ^b   Rousarova, M ^b   Finek, J ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Department of Nuclear Medicine ^*  (Czech Republic)

Author keywords

Breast cancer; Colorectal cancer; Therapy control; Thymidine kinase; Tumor markers

Indexed keywords

THYMIDINE KINASE;

BREAST CANCER; CANCER DIAGNOSIS; CANCER RELAPSE; CLINICAL FEATURE; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RADIORECEPTOR ASSAY; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; UTERINE CERVIX CANCER;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOASSAY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL;

EID: 34250692989     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Chuanjing W, Rong-Jiang Y, Ji Z, Shing B, Pinggan Z, Yongrong M, Jianping W and Qimin H: Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. Immunol Meth 277: 157-169, 2003.
2. Wu J, Mao Y, He L, Wang N, Wu C, He Q and Skog S: A new cell proliferating marker: cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinoma. Anticancer Res 20(6C): 4815-4820, 2000.
3. Topolcan O, Holubec L Jr, Finek J, Stieber P, Holdenrieder S, Lamerz R, Holubec L Sen, Svobodova S, Visokai V and Lipska L: Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy. Anticancer Res 25(3A): 1831-1833, 2005.
4. Lejcko J, Jungerova J, Topolcan O and Koza V: Thymidine kinase in malignant lymphogranuloma and Non-Hodgkin Lymphoma. Prakt Lék 72(5): 171-173, 1992.
5. Poley S, Stieber P, Nussler V et al: Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma. Anticancer Res 17(4B): 3025-3029, 1997.
6. Christiansen I, Gildlof C, Kalkner KM et al: Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with tumour burden, disease activity and other prognostic markers. Br J Haematol 92(3): 639-646, 1996.
7. Thomas WM, Robertson JF, McKenna PG, O'Neill KL, Robinson MH and Hardcastle JD: Serum thymidine kinase in colorectal neoplasia. Eur J Surg Oncol 21(6): 632-634, 1995.
8. Robertson JF, O'Neill KL, Thomas MW, McKenna PG and Blarney RW: Thymidine kinase in breast cancer. Br J Cancer. 62(4): 663-667, 1990.
9. Kausitz J, Kuliffay P and Pecen L: Correlation of cytosolic concentrations of ER, PS2, Cath-D, TPS, TK and cAMP in primary breast carcinomas. Neoplasma 41: 331-336, 1994.
10. Roman S, Christensen IJ, Chinot O et al: Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer. Int J Cancer 61: 7-12, 1995.
11. Chester SJ, Maimonis P, Vanzuiden P, Finklestein M, Bookout J and Vezeridis MP: A new radioimmunoassay detecting early stages of colon cancer: a comparison with CEA, AFP, and Ca 19-9. Dis Markers 9(5): 265-271, 1991.
12. Haglund C, Kuusela P, Roberts P and Jalanko H: Tumour marker CA 125 in patients with digestive tract malignancies. Scand J Clin Lab Invest 51(3): 265-270, 1991.
13. Kuusela P, Haglund C and Roberts PJ: Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer 63(4): 636-640, 1991.
14. Kornek G, Depisch D, Temsch EM and Scheithauer W: Comparative analysis of cancer-associated antigen CA-195, CA 19-9 and carcinoembryonic antigen in diagnosis, follow-up and monitoring of response to chemotherapy in patients with gastrointestinal cancer. J Cancer Res Clin Oncol 117(5): 493-496, 1991.
15. Ial'chenko NA, Lagutin VD, Lavik NN and Musin II: The clinical information value of an immunoenzyme study of the tumor markers CA-19-9, CEA and AFP in cancer of the stomach, pancreas, colon and rectum. Vopr Onkol 37(9-10): 921-924, 1991.
16. O'Neill KL, Buckwalter MR and Murray BK: Thymidine kinase: diagnostic and prognostic potential. Expert Rev Mol Diagn 1(4): 428-433, 2001.
17. Tanigawa N, Katoh Y, Fujii H, Shimomatsuya T, Aotake T and Yamakawa M: Prediction of prognosis of patients with gastrointestinal cancer based on thymidine uptake. Gan To Kagaku Ryoho 21(3): 388-394, 1994.
18. He Q, Fornander T, Johansson H, Johansson U, Hu GZ, Rutqvist LE and Skog S: Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res 26(6C): 4753-4759, 2006.